Clinical News

Recent Drug Approvals

February 2015, Vol 5, No 1 - FDA News

Jakafi Gets New Indication for Use in Patients with Polycythemia Vera The FDA approved ruxolitinib (Jakafi; Incyte Corporation) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The [ Read More ]

Recent Drug Approvals

November 2014, Vol 4, No 7 - FDA News

FDA Approves First Anti–PD-1: Pembrolizumab Indicated for Advanced Melanoma The FDA approved the first ­­anti–programmed death receptor-1 (PD-1) therapy, pembrolizumab (Keytruda; Merck), for patients with unresectable or metastatic melanoma and disease progression after treatment with other melanoma therapy, such as [ Read More ]